Back to the future: Rethinking the great potential of lncrnas for optimizing chemotherapeutic response in ovarian cancer

Abdelrahman M. Elsayed, Paola Amero, Salama A. Salama, Abdelaziz H. Abdelaziz, Gabriel Lopez-Berestein, Cristian Rodriguez-Aguayo

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Ovarian cancer (OC) is one of the most fatal cancers in women worldwide. Currently, platinum-and taxane-based chemotherapy is the mainstay for the treatment of OC. Yet, the emergence of chemoresistance results in therapeutic failure and significant relapse despite a consistent rate of primary response. Emerging evidence substantiates the potential role of lncRNAs in determining the response to standard chemotherapy in OC. The objective of this narrative review is to provide an integrated, synthesized overview of the current state of knowledge regarding the role of lncRNAs in the emergence of resistance to platinum-and taxane-based chemotherapy in OC. In addition, we sought to develop conceptual frameworks for harnessing the therapeutic potential of lncRNAs in strategies aimed at enhancing the chemotherapy response of OC. Furthermore, we offered significant new perspectives and insights on the interplay between lncRNAs and the molecular circuitries implicated in chemoresistance to determine their impacts on therapeutic response. Although this review summarizes robust data concerning the involvement of lncRNAs in the emergence of acquired resistance to platinum-and taxane-based chemotherapy in OC, effective approaches for translating these lncRNAs into clinical practice warrant further investigation.

Original languageEnglish (US)
Article number2406
Pages (from-to)1-35
Number of pages35
JournalCancers
Volume12
Issue number9
DOIs
StatePublished - Sep 2020

Keywords

  • Chemotherapy
  • Dysregulated expression
  • Long non-coding RNAs
  • Mechanisms of resistance
  • Ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Back to the future: Rethinking the great potential of lncrna<sub>s</sub> for optimizing chemotherapeutic response in ovarian cancer'. Together they form a unique fingerprint.

Cite this